Fat-Dissolving Injections: Approved Uses, Unapproved Products and Risks

Fat dissolving injections are not a generally approved treatment for fat throughout the body. In the United States, Kybella and an FDA-approved generic deoxycholic acid injection have a narrow approved use: improving the appearance of moderate-to-severe fullness caused by fat under the chin in adults. FDA's September 15, 2026 safety communication reinforced that boundary and highlighted persistent lumps and serious effects reported with use outside this area. Understanding the exact product, proposed treatment area and possible complications matters more than the treatment's marketing name.

1. Which Fat-Dissolving Injections Are FDA Approved?

Deoxycholic acid is a cytolytic medicine, meaning it breaks down cells. Its cosmetic use involves breaking down fat cells in the submental region, the area beneath the chin. This procedure is also called injection lipolysis.

FDA's September 2026 communication confirms that both Kybella and a generic deoxycholic acid injection are approved for the specified adult under-chin indication. An older FDA consumer page still describes Kybella as the only approved injectable. That brand-only wording is incomplete when read alongside the newer communication.

Approval does not extend to fat elsewhere simply because the same medicine is used. FDA specifically recommends against deoxycholic acid injections outside the submental region.

2. Is Under-Chin Fullness Actually Caused by Treatable Fat?

The assessment should come before choosing an injection. Kybella's prescribing information directs clinicians to consider other explanations for fullness, including an enlarged thyroid or neck lymph nodes. A consultation is therefore more than deciding whether someone wants a smaller contour.

Skin laxity means loose skin. Prominent platysmal bands are visible bands involving a superficial neck muscle. The label cautions that reducing fat in people with substantial laxity or prominent bands can produce an unwanted appearance. Removing fat is not the same goal as correcting loose skin or muscle bands.

A useful consultation question is: What is contributing to the contour I am concerned about, and which part would this medicine actually change? Ask the clinician to explain the finding rather than treating the phrase “double chin” as a diagnosis.

This is a localized appearance treatment, not an approved weight-loss treatment. If the goal is weight management, that requires a different clinical discussion. If loose skin is the main concern, ask whether an assessment focused on skin and neck structure would be more appropriate than fat reduction.

3. What Changed in September 2026?

The September 15 FDA communication described additional labeling warnings about serious reactions with use outside the approved under-chin area and about injection-site nodules and masses. Nodules and masses are lumps; some may not resolve and may require medical intervention. They have been reported after both under-chin treatment and treatment elsewhere.

For unapproved treatment sites, FDA described reports including blurred or reduced vision, involuntary eye contractions, muscle or nerve damage, weakness, numbness and difficulty walking. These reports are a reason not to treat body-wide marketing as an extension of the approved use.

3.1 What Safety Reports Can and Cannot Tell You

Spontaneous reports are accounts submitted after a suspected adverse event, rather than events collected from every treated person in a defined study. They can help regulators identify problems that need investigation, but they do not provide the denominator needed to calculate how often a complication occurs.

FDA explains that reports can be incomplete, duplicated or unverified. The existence of a report does not prove that the medicine caused that person's symptoms. Equally, these limitations do not mean a warning should be dismissed. The appropriate reading is that FDA reviewed safety information and strengthened warnings, not that every report establishes causation or a predictable individual risk.

4. Risks Within the Approved Treatment Area

Under-chin use is not risk-free. Common reactions listed in the prescribing information include swelling, bruising, pain, numbness, redness and firmness. “Nonsurgical” should not be understood to mean that recovery is immediate or complications cannot occur.

Other labeled concerns include nerve injury that can cause an uneven smile or facial weakness, difficulty swallowing, blood-vessel injury, hair loss at injection sites, open sores, tissue death and infection. Tissue death is also called necrosis. Persistent nodules or masses deserve assessment rather than an assumption that every lump is routine swelling.

Ask the treating clinician to distinguish expected reactions from changes requiring examination. A generic assurance that “lumps are normal” is not an adequate response to a persistent, worsening or otherwise concerning lump.

5. Unapproved Products and Product Authenticity

FDA identifies products marketed under names including Aqualyx, Lipodissolve, Lipo Lab and Kabelline as unapproved fat-dissolving injections in the United States. Reports involving unapproved products include permanent scarring, serious infections, skin deformities, cysts and deep, painful knots. Availability online or in a clinic does not establish FDA approval.

An ingredient name alone is not enough to verify a product. Ask for the exact medicine and manufacturer, whether that specific product is FDA approved, and how the practice obtains it. An FDA-approved generic is not the same thing as an unapproved mixture described as a generic alternative.

Useful questions about authenticity include:

• Can the clinician identify the product before treatment and document it in the medical record?
• Can the practice explain its supply source and retain the product's lot information?
• Does the proposed use match the approved indication, or is a different body area being offered?

These questions support transparency; they are not a way for a consumer to authenticate an injectable by appearance. FDA advises against purchasing fat-dissolving products online for self-injection.

6. Qualified Administration and a Meaningful Consultation

These injections belong in professional medical care. FDA says only health care providers should administer Kybella and warns about complications associated with unsafe practices and personnel who may not be properly licensed. A med-spa setting or a training certificate should not replace checking the administrator's professional license and lawful scope of practice in your state.

Before consenting, ask:

• Who will assess me, prescribe the medicine and administer it?
• What experience do you have assessing under-chin anatomy and managing complications?
• How does the September 2026 warning affect your consent discussion?
• Who can examine me promptly if I develop a lump, swallowing problem or facial weakness?
• What would make you recommend no treatment or a different assessment?

Tell the clinician about previous face or neck procedures, swallowing difficulties, bleeding problems, medicines and supplements, allergies, pregnancy or breastfeeding, and possible infection in the area. Individual clinical advice is necessary because the cause of fullness, medical history and treatment risks cannot be established from an article or photograph alone.

7. When to Get Medical Care After Injections

Contact a medical professional immediately for difficulty swallowing, an uneven smile, facial weakness, significant face or neck pain or tightness, or concerning injection-site changes. MedlinePlus also identifies sores, drainage, blackened skin, fever, redness, swelling and nodules or masses as reasons for immediate contact. Do not wait for a routine cosmetic follow-up to raise these symptoms.

If you have trouble breathing, collapse or cannot be awakened, call 911. These examples are not a complete list of serious complications. Seek care for other unusual or worsening symptoms, including visual changes or new weakness after treatment.

If the original provider is unavailable, seek medical care elsewhere. Share the product name, treatment date, treated area and any available packaging or treatment records. Be candid if the product came from an online seller or its identity is uncertain; that information can help the clinician assess what happened.

Patients and clinicians can also report suspected adverse events through FDA MedWatch. Reporting helps safety monitoring, but it does not replace medical assessment or treatment.

8. Alternatives and the Decision Not to Treat

No cosmetic treatment is also an option. Before comparing procedures, clarify whether the concern is localized fat, loose skin or something that needs medical investigation.

Some non-invasive body-contouring devices are authorized for particular uses and body sites. Their authorization does not apply to injected medicines. FDA emphasizes that these devices have technology-specific risks, may not produce the desired effect and are not treatments for obesity or weight loss. Liposuction is different again: it surgically removes fat through small incisions. Neither category should be presented as an automatically safer substitute based on unrelated safety lists.

The central decision is not simply whether fat dissolving injections “work.” It is whether an identified, approved product has an appropriate role for the particular concern, whether its limits and risks are acceptable, and whether reliable follow-up is available. Under-chin approval should never be presented as approval for general body-fat treatment.